Research on how long people stay on GLP-1 treatment uses different populations and measures. This study found a median observed duration of 240 days for GLP-1 treatment in insured adults with type 2 diabetes and obesity [1].
What the cohort counted
Researchers analyzed 342,932 treatment starts among people with private or Medicare Advantage coverage (n = 335,605). About 61% of starts were GLP-1 drugs. The rest were SGLT2 inhibitors or metabolic bariatric surgery [1].
Median duration was 240 days for GLP-1 drugs and 254 days for SGLT2 inhibitors. At the one-year mark, 53.0% and 56.0%, respectively, were using their initial treatment. Duration and use on a given date are separate measures.
How to read the duration figures
In a comparison of annual plans and falling prices, a billing term describes a payment commitment. This cohort study measured observed treatment patterns. Its duration estimate cannot tell someone how long their care should last.
Everyone in the cohort had both diabetes and obesity. The study does not establish treatment duration for people without diabetes or those paying entirely out of pocket.